Stay updated on Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-06T20:48:50.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A 403 Forbidden error page is now displayed, including a 403 header and a Home link, indicating restricted access to the study record rather than the usual ClinicalTrials.gov content. The new page presents an access-denied state rather than the study details.
    Difference
    0.5%
    Check dated 2026-09-29T20:46:10.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error where the study record content was shown. This indicates access to the content is blocked, representing a non-substantive access issue rather than a content update.
    Difference
    21%
    Check dated 2026-09-22T22:59:01.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The page's revision label changed from v3.6.6 to v3.7.0, indicating a refresh of the page metadata rather than a modification to study details.
    Difference
    0.1%
    Check dated 2026-09-15T21:36:40.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    The page’s revision tag was updated from v3.6.5 to v3.6.6, indicating a minor internal update. There are no changes to the visible content or functionality presented on the study page.
    Difference
    0.1%
    Check dated 2026-09-01T18:10:39.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.6.5, replacing the previous Revision: v3.6.4. This reflects a minor update to the page's revision tag rather than a change to study data or content.
    Difference
    0.0%
    Check dated 2026-08-11T15:52:30.000Z thumbnail image

Stay in the know with updates to Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page.